Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men

Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men

Bibliographic Details
Main Authors:	Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, Ahmad Alamadi, Sally A. Mahmoud, Aala Hassan, Shuping Xu, Jian Li, Dongfang Liu, Adam Abdul Hakeem Baidoo, Dima Ibrahim, Mojtaba Alhaj, Yuanxin Chen, Qiang Zhou, Liangzhi Xie
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-01-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-024-44729-x

Similar Items

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
by: Suad Hannawi, et al.
Published: (2023-07-01)

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trialResearch in context
by: Suad Hannawi, et al.
Published: (2023-01-01)

Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated Adults
by: Suad Hannawi, et al.
Published: (2024-09-01)

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trialResearch in context
by: Suad Hannawi, et al.
Published: (2023-10-01)

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
by: Ngoc H. Tan, et al.
Published: (2022-11-01)

Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
by: Luca M. Zaeck, et al.
Published: (2024-05-01)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
by: Ramil R. Mintaev, et al.
Published: (2023-04-01)

An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19
by: Sneh Lata Gupta, et al.
Published: (2022-12-01)

Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study
by: Suad Hannawi, et al.
Published: (2023-08-01)

Characterizing healthcare worker attitudes toward the bivalent COVID-19 booster
by: Kathryn Willebrand, et al.
Published: (2023-06-01)

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination
by: Divyasha Saxena, et al.
Published: (2023-05-01)

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
by: Snape, MD, et al.
Published: (2008)

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
by: Donald J. Alcendor, et al.
Published: (2023-04-01)

The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules
by: Eduardo Lazcano-Ponce, et al.
Published: (2018-12-01)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
by: Inge LeFevre, et al.
Published: (2023-05-01)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
by: Claire Vigne, et al.
Published: (2017-09-01)

Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth
by: Nathifa Moyo, et al.
Published: (2020-07-01)

Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
by: Guiqiang Wang, et al.
Published: (2025-12-01)

BRIDGING THE IMMUNOGENICITY OF A TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) FROM CHILDREN AND ADOLESCENTS TO ADULTS
by: C. Halim, et al.
Published: (2023-05-01)

The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review
by: Raksheeth Agarwal, et al.
Published: (2017-04-01)

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies
by: Abundio Balgos, et al.
Published: (2024-12-01)

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
by: Hui Zhao, et al.
Published: (2024-01-01)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
by: Giorgia Della Polla, et al.
Published: (2023-01-01)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
by: Li-Wei Shi, et al.
Published: (2023-01-01)

Immunogenic Evaluation of Bivalent Vaccine Candidate against Enterohemorrhagic and Enterotoxigenic Escherichia coli
by: Ahmad Karimi Rahjerdi, et al.
Published: (2019-09-01)

Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle
by: Clóvis Moreira, et al.
Published: (2018-09-01)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
by: Judith Kirstein, et al.
Published: (2018-09-01)

Factors associated with the decision to receive bivalent COVID-19 booster vaccination among health care personnel
by: Nicholas M. Mohr, et al.
Published: (2023-12-01)

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
by: Spyros Chalkias, et al.
Published: (2023-08-01)

Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial
by: Jihai Tang, et al.
Published: (2024-02-01)

Immunogenicity of a bivalent adjuvanted glycoconjugate vaccine against salmonella typhimurium and salmonella enteritidis.
by: Fiorino, F, et al.
Published: (2017)

Trial Evaluation of Protection and Immunogenicity of Piscine Bivalent Streptococcal Vaccine: From the Lab to the Farms
by: Korntip Kannika, et al.
Published: (2022-09-01)

Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals
by: Xiao-Juan Yu, et al.
Published: (2020-07-01)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01)

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
by: Juliana Park, et al.
Published: (2021-07-01)

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
by: Thomas Roberts, et al.
Published: (2024-01-01)

The evolution of vaccine hesitancy through the COVID-19 pandemic: A semi-structured interview study on booster and bivalent doses
by: Jeanna Parsons Leigh, et al.
Published: (2024-12-01)

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
by: Mark Turner, et al.
Published: (2020-10-01)

Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial
by: Ruizhi Zhang, et al.
Published: (2024-07-01)

The Relevance of Tetravalent Influenza Vaccines. World experience
by: A. D. M. E. Osterhaus
Published: (2018-09-01)